Literature DB >> 15613172

Significance of migrainous features in cluster headache: divalproex responsiveness.

S D Wheeler1.   

Abstract

Two patients with cluster headache and prominent migrainous features are described and a shared migraine and cluster headache pathophysiology is discussed. Both patients failed routine cluster headache pharmacotherapy, one failed multiple operative interventions; however, both remitted on divalproex. It is suggested that migrainous features be assessed in cluster headache and divalproex initiated before pursuing invasive procedures.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 15613172     DOI: 10.1046/j.1526-4610.1998.3807547.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  8 in total

1.  Trigeminal autonomic cephalgias.

Authors:  Rafael Benoliel
Journal:  Br J Pain       Date:  2012-08

Review 2.  New treatments in cluster headache.

Authors:  Todd D Rozen
Journal:  Curr Neurol Neurosci Rep       Date:  2002-03       Impact factor: 5.081

3.  Cluster Headache and Cluster Variants.

Authors:  Marc E. Lenaerts
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

Review 4.  Evidence-based treatments for cluster headache.

Authors:  Rubesh Gooriah; Alina Buture; Fayyaz Ahmed
Journal:  Ther Clin Risk Manag       Date:  2015-11-09       Impact factor: 2.423

5.  The use of baclofen in cluster headache.

Authors:  R Hering-Hanit; N Gadoth
Journal:  Curr Pain Headache Rep       Date:  2001-02

Review 6.  Treatment and management of cluster headache.

Authors:  D W Dodick; D J Capobianco
Journal:  Curr Pain Headache Rep       Date:  2001-02

Review 7.  Premonitory symptoms in cluster headache.

Authors:  E Raimondi
Journal:  Curr Pain Headache Rep       Date:  2001-02

8.  Cranial Autonomic Features in Migraine and Migrainous Features in Cluster Headache.

Authors:  Derya Uluduz; Semih Ayta; Aynur Özge; Osman Özgür Yalin; Guülhan Örekici Temel; Bahar Taşdelen
Journal:  Noro Psikiyatr Ars       Date:  2016-07-15       Impact factor: 1.339

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.